Prediction of rodent carcinogenicity using the DEREK system for 30 chemicals currently being tested by the National Toxicology Program. The DEREK Collaborative Group. by Marchant, C A
Prediction of Rodent Carcinogenicity Using
the DEREK System for 30 Chemicals Currently
Being Tested bythe National Toxicology
Program
Carol A. Marchant1 and The DEREK Collaborative Group2
1LHASA UK, School of Chemistry, University of Leeds, Leeds, United
Kingdom; 2The DEREK Collaborative Group is an international consortium
of representatives from pharmaceutical and agrochemical companies,
regulatory authorities and academia. The Group makes recommendations
for, and advises on, the development ofthe DEREK system.
DEREK is a knowledge-based expert system for the qualitative prediction of toxicity. The DEREK
system has been used to predict the carcinogenicity in rodents of the 30 chemicals in the second
National Toxicology Program (NTP) carcinogenicity prediction exercise. Seven of the chemicals
were predicted to be carcinogens. For 23 chemicals, there was no evidence in the DEREK knowl-
edge base to suggest carcinogenic activity. Supplementary data from a variety of sources have
been evaluated by human experts to assess confidence in each DEREK prediction. These sources
included standard toxicology reference texts, genotoxicity and subchronic toxicity assay results for
each chemical, as well as Salmonella mutagenicity and carcinogenicity data for close structural
analogues. This process has led to the proposal of a number of improvements to the DEREK
carcinogenicity knowledge base. - Environ Health Perspect 104(Suppl 5):1065-1073 (1996)
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Introduction
The ability to predict the carcinogenic
potential ofa chemical without recourse to
long-term animal bioassays is an important
tool in the effective prioritization ofchemi-
cal testing programs. Benefits may also be
obtained in terms of animal welfare and a
reduction in the number ofanimals used in
testing. Comparison of predictions with
experimental data can additionally high-
light gaps in our understanding of the
mechanisms ofthe carcinogenic process. In
the first National Toxicology Program
(NTP) carcinogenicity prediction exercise,
a variety of techniques were used to
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prospectively predict the outcome of
rodent carcinogenicity bioassays for 44
chemicals that were at that time being
tested by the NTP (1). DEREK (2,3), a
knowledge-based expert system for the
qualitative prediction of toxicity, per-
formed marginally better than other com-
puter methods. For the 40 chemicals for
which bioassay data are now available,
60% of the predictions made by DEREK
were correct, ifchemicals giving an equivo-
cal bioassay outcome are assumed to be
noncarcinogenic (2,4). In the same exer-
cise, 75% of predictions made by human
experts, using a combination ofstructural
alerts, genotoxicity, and subchronic toxicity
data, were correct (4). Ashby and Tennant
(4) have suggested that, for diverse chemi-
cal sets, predictivity by any method is
currently limited to a maximum of 80%,
as a consequence ofinadequate knowledge
and uncertainties in the evaluation of
experimental bioassay data. Recently, the
National Institute of Environmental
Health Sciences (NIEHS) has invited
predictions for the outcome of rodent
carcinogenicity bioassays for a further 30
chemicals. This article describes the
predictions made using the DEREK sys-
tem and the subsequent evaluation of
these predictions by human experts using
supplementary data from a number of
sources. This illustrates the intended use
of DEREK as an aid to toxicological
hazard assessment in conjunction with
other methods.
Method
The DEREK system has been described in
detail elsewhere (2,3). DEREK makes its
predictions based on a series of rules con-
tained in the DEREK knowledge base.
Each rule describes the relationship
between a structural feature or toxicophore
and its associated toxicity. In addition to
carcinogenicity, toxicological end points
currently covered by the DEREK system
include mutagenicity, skin sensitization,
irritancy, teratogenicity, and neurotoxic-
ity. To use the system interactively, a query
structure can either be drawn at the
DEREK graphical interface, retrieved from
a previously saved structure file, or
imported in MOLfile format. The struc-
ture is then processed, and the system com-
pares structural features in the target
compound with the toxicophores described
in its knowledge base. A rule is activated or
fires when the toxicophore it describes is
found to be present in the structure under
consideration. The toxicophore is high-
lighted to the user, and the toxic effect is
displayed. A summary of the information
used to compile the rule can be viewed if
the reference screen is selected. In the case
of carcinogenicity, for example, this
information can additionally include
details such as organ or species specificity,
where sufficient supporting data exist. For
query structures that fire more than one
rule, each toxicophore is displayed sequen-
tially on the screen with its associated haz-
ard. In the event that no toxicological
hazard is perceived, the system reports that
no toxicophores have been identified in the
structure. New DEREK rules are written
following a detailed review of published
sources oftoxicological, mechanistic, and
chemical data. The DEREK knowledge
base also contains a series of rules that
describe toxicophores for carcinogenic
activity derived from a publication of the
U.S. Food and DrugAdministration (FDA)
(5). These FDA rules are intended to allow
regulatory concerns to be anticipated.
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Structures for each ofthe 30 chemicals
in the exercise were processed through the
DEREK system using all rules in the
knowledge base. Two of the chemicals (1-
chloro-2-propanol and the sodium salt of
xylenesulfonic acid) were known to be
mixtures of positional isomers. In both
cases, a single representative isomer was
processed, namely 1-chloro-2-propanol
and the sodium salt of 3,4-dimethyl-ben-
zenesulfonic acid. Citral was also reported
to be a mixture ofcisand transisomers, but
since no DEREK rule currently differenti-
ates between the toxicity ofsuch geometric
isomers, no account was taken of this.
Other chemicals were known to contain up
to 11% impurity, but since these impuri-
ties were not identified, they could not be
processed. As a result, carcinogenic activity
arising from the presence of unidentified
impurities in the chemicals under test will
not be predicted. In the event that a chem-
ical fired one or more DEREK rules for
carcinogenicity, it was predicted to be a
carcinogen. No distinction was made
between carcinogenicity predictions based
on different rule types, although it has
been suggested that the broader definition
of the toxicophores that form the basis of
some FDA rules may lead to more false
positive predictions ofcarcinogenic activity
compared to other rules in the DEREK car-
cinogenicity knowledge base (2). Otherwise,
DEREK contained no evidence in its
knowledge base to suggest carcinogenic
activity. In some cases, this may be a conse-
quence ofthe absence from the knowledge
base of an as yet unidentified toxicophore.
For the purposes of the current exercise,
however, it was interpreted as a prediction
ofnoncarcinogenicity.
Supplementary data from a number of
sources were evaluated by human experts
to assess confidence in each DEREK pre-
diction. By default, all predictions were ini-
tially assigned a confidence level of
moderate, and this was then up- or down-
graded in the light of additional informa-
tion. Where supplementary data were
considered to be predominantly in support
ofa DEREK prediction, the prediction was
assigned a high level of confidence.
Conversely, evidence judged to be predom-
inantly contradictory led to a low
confidence level prediction. A moderate
confidence level was assigned to DEREK
predictions for which the available evi-
dence was considered either insufficient or
conflicting. In all cases, confidence levels
relate to the potential for rodent carcino-
genicity by the given route ofexposure and
may not necessarily be of relevance to
human health.
Genotoxicity and subchronic toxicity
data for each chemical were made available
to participants by NIEHS. Since many car-
cinogens are known to exhibit activity at
least in part by a genotoxic mechanism, in
vivo genotoxicity was considered evidence
ofpotential carcinogenicity. In the absence
of in vivodata, the results of in vitro assays,
particularly the Ames test, were evaluated.
Chemicals that gave a positive response in
the Ames test were considered possible in
vivo genotoxins, whereas those that gave a
negative response were in general judged
unlikely to be so.
Although a well-defined relationship
remains to be established between carcino-
genicity and the observation of toxicity in
the same organ (6), significant toxicity in a
subchronic study was considered a possible
early indicator ofpotential carcinogenic
activity. Particular weight was given to tox-
icity observed in an organ for which an
increased incidence of tumors had been
reported following administration of the
compound itself, its metabolic precursor,
metabolite, or close structural analogue.
Such evidence was used as the basis for the
prediction of the likely site of tumor for-
mation for a number ofchemicals. A com-
parison of the predicted tumor site with
the outcome of the experimental bioassay
will provide useful evidence either for or
against the reasoning behind the predic-
tion, depending on whether or not it is
found to be correct. For several chemicals,
lesions observed in the subchronic study
were thought likely to be related to the
route of exposure, and may reflect a pro-
longed irritant effect that could lead to
nongenotoxic carcinogenicity.
Evidence from other miscellaneous
sources was also evaluated. This included
information contained in the DEREK ref-
erence screens and standard toxicology
reference texts and genotoxicity and car-
cinogenicity data for structurally related
compounds contained in the NTP
Salmonella mutagenicity (7-11) and Gold
carcinogenicity databases (12). DEREK
predictions of mutagenicity for chemicals
that were not predicted to be carcinogenic
were also noted.
Results
The predictions made by the DEREK
system are given in Table 1, together with
associated confidence levels derived by
human experts. The supplementary infor-
mation used to assess the confidence in
each DEREK prediction is summarized
below. Except where specifically refer-
enced, genotoxicity and subchronic toxicity
data are derived from studies sponsored
by the NTP, and are those supplied by
NIEHS. Subchronic studies were of90-day
duration, except where stated.
Table 1. Predictions forthe 30 chemicals in the second NTP carcinogenicity prediction exercise.
Chemical
No. Name Structure CAS no. DEREK predictiona Expert confidenceb
1 Scopolamine hydrobromidetrihydrate CH,\ 6533-68-2 Carcinogen Low
O
0
OH
2 Codeine clH3 76-57-3 Noncarcinogen High
N
CH,O 0 OH
3 1,2-Dihydro-2,2,4-trimethylquinoline CH, 147-47-7 Carcinogen Moderate
W\.- CH3
H CH3 (continued)
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Table 1. (continued)
Chemical
No. Name Structure CAS no. DEREK predictiona Expertconfidenceb
4 Nitromethane CH3-NO2 75-52-5 Carcinogen Moderate
5 Tetrahydrofuran
6 t-Butylhydroquinone
7 Ethylbenzene
-0
OH
C(CH3)3
OH
CH2CH3
8 Chloroprene
9 Cobalt sulfate heptahydrate CoS047 H20
109-99-9
1948-33-0
100-41-4
126-99-8
10026-24-1
Noncarcinogen
Noncarcinogen
Noncarcinogen
Carcinogen
Noncarcinogen
Moderate(female mouse);
high (rat, male mouse)
Low
Moderate
Moderate (mouse);
high (rat)
Low
10 D&C Yellow No. 11
11 Isobutyraldehyde
12 Molybdenum trioxide
13 1-Chloro-2-propanol
14 Diethanolamine
15 Phenolphthalein
16 Pyridine
- .- 0
0
CH
CHO
CH3
MoO3
CH2CHCH3
a OH
(HOCH2CH2)2NH
0
0
OH
OH
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8003-22-3
78-84-2
1313-27-5
127-00-4
111-42-2
77-09-8
110-86-1
Carcinogen
Noncarcinogen
Noncarcinogen
Carcinogen
Carcinogen
Noncarcinogen
Noncarcinogen
Moderate
Low
High
Low
Moderate
Moderate
Moderate (rat);
high (mouse)
(continued)
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Table 1. (continued)
Chemical
No. Name Structure CAS no. DEREK predictiona Expert confidenceb
17 Xylenesulfonic acid, sodium salt
18 Furfuryl alcohol
19 Primaclone
CH3
XCH3
SO3Na
O CH2OH
0
CH3CH2
- )NH
oN
H
1300-72-7
98-00-0
125-33-7
Noncarcinogen
Noncarcinogen
Noncarcinogen
High
Low
Low
20 Ethylene glycol monobutyl ether
21 Gallium arsenide
22 Isobutene
23 Methyleugenol
HOCH2CH20H,CH2CH2CH3
GaAs
CH3
CH3
OCH3
/ OCH3
24 Oxymetholone
25 Anthraquinone
26 Emodin
27 Citral
28 Sodium nitrite
CH3 OH
CH3 CH,
HOCH
H
0
OH 0 OH
CH3 OH
CH3
N CHO
CH3 CH3
NaNO2
29 Cinnamaldehyde
/ C=-CHO
30 Vanadium pentoxide V205
104-55-2
1314-62-1
Noncarcinogen
Noncarcinogen
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111-76-2
1303-00-0
115-11-7
93-15-2
Noncarcinogen
Noncarcinogen
Noncarcinogen
Noncarcinogen
Low
Moderate
Moderate (rat);
high (mouse)
Low
434-07-1
84-65-1
518-82-1
5392-40-5
7632-00-0
Noncarcinogen
Noncarcinogen
Noncarcinogen
Noncarcinogen
Noncarcinogen
Low
Moderate
Low
Moderate
Low
"Qualitative predictions of carcinogenic activity were made using the DEREK system; bA level of either high, moderate, or low confidence in each DEREK prediction was
derived by human expert evaluation of supplementary data from a number of sources, including genotoxicity and subchronic toxicity data supplied to participants by NIEHS.
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Supplemental Information on the
ChemicalsTestedbyNumber
1. Scopolamine Hydrobromide Trihydrate.
DEREK predicts scopolamine hydrobromide
to be a carcinogen, since it contains an
epoxide group that may lead to DNA alky-
lation. Although simple epoxides are gener-
ally mutagenic to Salmonella (7-11),
scopolamine hydrobromide itselfwas not
positive in the Ames test. This suggests a
possible lack of electrophilic reactivity.
Structural analogues, endrin and dieldrin,
which similarly contain an epoxide fused to
a bridged ring system, are also nonmuta-
genic in Salmonella (7,9). Since effects seen
in the subchronic study were not judged
significant, the confidence in DEREK's
prediction ofcarcinogenicity is low.
2. Codeine. Codeine phosphate was
not positive in the Ames test. No histo-
pathological effects were observed in the
subchronic study. The confidence in
DEREK's prediction ofnoncarcinogenicity
is therefore high.
3. 1,2-Dihydro-2,2,4-trimethylqui-
noline (monomer). DEREK predicts
1,2-dihydro-2,2,4-trimethylquinoline to
be a carcinogen on the basis ofthe possible
nitrosation by gut microflora of the sec-
ondary amine functionality, with the
resulting nitrosamine leading to DNA
alkylation. Since in the current case the
compound is being administered by skin
painting, this mechanism was not consid-
ered relevant here. A lack of genotoxic
activity is supported by negative results
in the Ames test (although Salmonella
lack the ability to nitrosate) and a mouse
micronucleus assay. Skin lesions, probably
related to the route ofexposure, were, how-
ever, observed in the subchronic study.
The overall confidence in the prediction of
carcinogenicity is therefore moderate,
although any activity was thought unlikely
to result from the mechanism suggested
by DEREK.
4. Nitromethane. Nitromethane is
predicted by DEREK to be a carcinogen on
the basis that it is an aliphatic nitro com-
pound. Nitromethane, was however, not
mutagenic in theAmes test, and gave a neg-
ative response in a mouse micronucleus
assay, indicating a lack of genotoxic
activity. This is consistent with reported
findings that genotoxicity may be restricted
to secondary alkyl nitro compounds (13).
Degeneration of the olfactory epithelium,
probably related to the route ofexposure,
was seen in the subchronic study. The
overall confidence in DEREK's prediction
ofcarcinogenicity is therefore moderate.
5. Tetrahydrofuran. Tetrahydrofuran
gave a negative response in the Ames test
and a chromosome aberration assay. A
mouse micronucleus assay gave negative
and equivocal responses. Degeneration of
the female mouse adrenal gland was
observed in the subchronic study. The
confidence in DEREK's prediction ofnon-
carcinogenicity is considered high in both
sexes ofthe rat and in the male mouse, and
moderate for the female mouse.
6. t-Butylydroquinone. t-Butylhydro-
quinone was not mutagenic in the Ames
test, in keeping with other simple hydro-
quinones and their 0-methyl derivatives in
the NTP Salmonella mutagenicity database
(7-11). The structural analogue, hydro-
quinone, gives a negative response in the
Ames test (7), and is reported to be a rodent
carcinogen, causing increased incidences of
tubular cell adenomas ofthe kidney in male
rats, ofmononuclear cell leukemia in female
rats, and of hepatocellular neoplasms in
female mice (14). Butylated hydroxyanisole,
a possible metabolic precursor of t-butylhy-
droquinone, is listed in the Gold carcino-
genicity database as a rat carcinogen (12),
causing an increased incidence offorestom-
ach tumors (15). Toxic effects observed in
the subchronic studyinclude nasal hyperpla-
sia or inflammation and mouse forestomach
hyperplasia, which was probably related to
the route of exposure. Confidence in
DEREK's prediction of noncarcinogenicity
is low, with the forestomach identified as a
possible site oftumor formation.
7. Ethylbenzene. Ethylbenzene gave
negative responses in the Ames test and a
mouse micronucleus assay. No chemically
related lesions were observed in the sub-
chronic study. Increased tumor formation
in rats following administration of ethyl-
benzene by gavage has been reported (16).
The confidence in DEREK's prediction of
noncarcinogenicity is assigned as moderate.
8. Chloroprene. DEREK predicts
chloroprene to be a carcinogen because it is
a halogenated alkene that may lead to
DNA alkylation following metabolic epox-
idation. It gave a negative response in the
Ames test and for mouse micronucleus,
chromosome aberration, and sister chro-
matid exchange assays. Hepatic lesions
were observed in the rat subchronic study,
together with toxicity of the respiratory
tract, which was probably related to the
route of exposure. No significant toxicity
was observed in the mouse subchronic
study. A number ofchlorinated alkenes are
included in the Gold carcinogenicity data-
base. In several cases, sites of increased
tumor incidence include the liver, kidney,
and respiratory tract (12). A 2-year inhala-
tion study ofchloroprene in the rat showed
no evidence ofcarcinogenic activity (17),
although a higher dose is to be used in the
current bioassay. Other carcinogenicity
studies ofchloroprene in rodents have been
considered inadequately reported for evalu-
ation or led to no evidence ofcarcinogenic
activity (18). The confidence in DEREK's
prediction ofcarcinogenicity is moderate
in the mouse and high in the rat. The liver
and respiratory tract are identified as possi-
ble sites oftumor formation.
9. Cobalt Sulfate Heptahydrate.
Cobalt sulfate was weakly mutagenic in the
Ames test. It has been suggested that cobalt
(II) compounds may interfere with DNA
repair processes (19). Respiratory tract
lesions were observed in the subchronic
study, and were probably related to the
route of exposure. The confidence in
DEREK's prediction ofnoncarcinogenicity
is low.
10. D&C Yellow No. 11. DEREK
predicts D&C Yellow No. 11 to be a car-
cinogen on the basis ofthe presence ofthe
quinoline ring, which may damage DNA
following epoxidation. It was weakly
mutagenic in the Ames test in the pres-
ence ofS9 but gave a negative response in
a mouse micronucleus assay. Hepatic
lesions were observed in both rats and
mice in the subchronic study, together
with hyaline dropletlike structures in
the renal tubules of the male rat, which
suggests the possibility ofa2l,-globulin
nephropathy. This requires binding to the
a2,-globulin protein at a site offinite size
(20), which was considered possibly too
small to accommodate the D&C Yellow
No. 11 structure. Overall, the confidence
in DEREK's prediction ofcarcinogenicity
is moderate.
11. Isobutyraldehyde. DEREK predicts
isobutyraldehyde to be a mutagen, since
it is an alkyl aldehyde and may exhibit
electrophilic and hence DNA reactivity. It
gave an equivocal response in the Ames
test. Simple aldehydes, apart from formal-
dehyde, are typically negative in the Ames
test, as evidenced by entries in the NTP
Salmonella mutagenicity database (7-11).
The subchronic study includes the obser-
vation of respiratory tract lesions, which
were probably related to the route ofexpo-
sure. Acetaldehyde and formaldehyde are
both listed in the Gold carcinogenicity
database as causing tumors of the nasal
cavity (12). The confidence in DEREK's
prediction of noncarcinogenicity is low,
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and the respiratory tract is identified as a
possible site oftumor formation.
12. Molybdenum Trioxide. Molybde-
num trioxide gave a negative response in
the Ames test, and no microscopic or gross
pathology lesions were observed in either
rats or mice in the subchronic study.
Confidence in DEREK's prediction of
noncarcinogenicity is therefore high.
13.1-Chloro-2-propanol. DEREK
identifies 1-chloro-2-propanol to be a car-
cinogen on the basis ofthe presence ofthe
alkyl chloride functionality, which may
lead to DNA alkylation. 1-Chloro-2-
propanol may also undergo an elimination
reaction leading to the formation of an
epoxide. It gave a positive response in the
Ames test but was negative in a mouse
micronucleus assay. 2-Chloroethanol, a
close structural analogue, is similarly
reported to give a positive response in the
Ames test and a negative result in an
in vivo mouse micronucleus assay; it gave
no evidence of carcinogenicity in a rat
and mouse skin-painting carcinogenicity
study (21,22). Lesions observed in the
subchronic study were not considered
significant. The confidence in DEREK's
prediction ofcarcinogenicity is low.
14. Diethanolamine. Diethanolamine
is identified by DEREK as a carcinogen on
the basis ofthe possible nitrosation by gut
microflora of the secondary amine func-
tionality, with the resulting nitrosamine
leading to DNA alkylation. As in the case
of 1,2-dihydro-2,2,4-trimethylquinoline,
such nitrosation was not considered rele-
vant in this case since administration is by
skin painting and not by a gastric route.
Diethanolamine gave a negative response
in the Ames test and a mouse micronucleus
assay. Observations in the subchronic
study included skin lesions related to the
route of exposure. The overall confidence
in the prediction of carcinogenicity is
therefore moderate, although any activity
was thought unlikely to result from the
mechanism suggested by DEREK.
15. Phenolphthalein. Phenolphthalein
was not mutagenic in an Ames test but
gave a positive response in a mouse micro-
nucleus assay. No histopathological lesions
were seen in the rat subchronic study, and
observations in the mouse study were not
judged to be significant. Confidence in
DEREK's prediction ofnoncarcinogenicity
is moderate.
16. Pyridine. Pyridine was not muta-
genic in the Ames test. No lesions were
observed in the mouse subchronic study.
In addition to changes in the liver ofboth
male and female rats in the subchronic
study, male rat kidney lesions were also
observed and were reported to be similar to
those described for x2,,-globulin nephro-
pathy. The pyridine structure was, how-
ever, considered probably too small for
effective binding to the a2,,-globulin pro-
tein. The confidence in DEREK's predic-
tion of noncarcinogenicity is high in the
mouse and moderate in the rat.
17. XylenesulfonicAcid, Sodium Salt.
Xylenesulfonic acid gave a negative result
in the Ames test. Minimal epidermal
hyperplasia observed in the subchronic
study in male rats and mice, and probably
related to the route of exposure, was not
considered significant. The confidence in
DEREK's prediction ofnoncarcinogenicity
is high.
18. FurfurylAkohol. Furfuryl alcohol
was negative in the Ames test, and in chro-
mosome aberration and sister chromatid
exchange assays. Lesions of the respiratory
tract, which were probably related to the
route of exposure, were observed in the
subchronic study. Furfuryl alcohol is read-
ily metabolized to furoylglycine, furoic acid
and furanacrylic acid via furfural in the rat
(23). Furfural itself has been reported to
show carcinogenic activity when adminis-
tered by gavage (24). Furan is also carcino-
genic (25). The confidence in DEREK's
prediction ofnoncarcinogenicity is low.
19. Primaclone. Primaclone gave a
positive response in the Ames test in the
absence ofS9, but the mouse micronucleus
assay was negative. Hepatic lesions were
observed in both rats and mice in the
subchronic study, together with renal
nephropathy in the male rat kidney.
aX2t-Globulin nephropathy was considered
unlikely, however, since hyaline-droplet
formation was not described. Primaclone
is metabolized to phenobarbital in rodents
(26). Phenobarbital and its sodium salt
are listed in the Gold carcinogenicity data-
base as rat and mouse liver carcinogens
(12), and may also lead to an increased
incidence of thyroid tumors, following
induction of thyroxine glucuronyltrans-
ferase (27). Confidence in DEREK's pre-
diction of noncarcinogenicity is low, and
the liver is identified as a possible site of
tumor formation.
20. Ethylene GlycolMonobutylEther
(2-Butoxyethanol). Ethylene glycol
monobutyl ether gave a negative response
in the Ames test. Lesions were observed at
a number of sites in both the rat and
mouse subchronic study. Ethylene glycol
monobutyl ether is metabolized to
2-butoxyacetic acid (28), which is struc-
turally similar to known peroxisome pro-
liferators (29). Peroxisome proliferation
was considered unlikely in the current
instance, however, since although lesions
were observed in the rat liver, these did not
include the hepatocellular hyperplasia and
hypertrophy that characterize this process
(29). Diethylene glycol, a structural ana-
logue of ethylene glycol monobutyl ether,
was also negative in the Ames test when
tested by the NTP (9) and is listed in the
Gold carcinogenicity database as a rat
urinary bladder carcinogen (12). The level
of confidence in DEREK's prediction of
noncarcinogenicity is low.
21. Gallium Arsenide. Gallium
arsenide gave a negative result in the Ames
test and in a mouse micronucleus assay.
One of its metabolites, dimethylarsinic
acid (30), is also reported to be nonmuta-
genic to Salmonella (7). Observations in
the subchronic study include respiratory
tract lesions, which were probably related
to the route ofexposure. Ashby et al. (31)
have identified arsenic-containing com-
pounds as potential carcinogens, although
there is currently only limited evidence
for the carcinogenicity of arsenic and its
compounds in rodents (32). The level of
confidence in DEREK's prediction ofnon-
carcinogenicity is moderate.
22. Isobutene. Isobutene gave a
negative response in the Ames test, but its
epoxide metabolite has been reported to be
mutagenic, although very high concentra-
tions are required and the epoxide has been
demonstrated to be efficiently detoxified by
liver enzymes (33). No histopathological
lesions were observed in the mouse sub-
chronic study, but nasopharyngeal duct
goblet cell hypertrophy was observed in
the rat and was probably related to the
route of exposure. A structurally related
compound, propylene, was found not to be
carcinogenic by inhalation (34). Confi-
dence in DEREK's prediction of noncar-
cinogenicity is high for the mouse and
moderate for the rat.
23. Methyleugenol. Methyleugenol
gave a negative response in the Ames test
and a mouse micronucleus assay, although
a positive response has been reported in an
in vitro unscheduled DNA synthesis (UDS)
assay (35). It has been suggested that a lack
ofactivity ofalkenylbenzenes in the Ames
test is most likely to be due to the failure of
metabolic activation (35). Methyleugenol
has also been reported to induce hepatic
tumors in male mice treated prior to wean-
ing (36). A number ofstructurally related
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alkenylbenzenes are included in the Gold
carcinogenicity database, with the liver a
common site ofincreased tumor incidence
(12). Eugenol, which may be formed by
enzymatic O-demethylation of methyl-
eugenol, led to an equivocal increase in
hepatic neoplasms in the mouse, although
it was not carcinogenic in the rat (37).
Methyleugenol induced liver lesions in
both rats and mice in the subchronic study,
in addition to lesions of the glandular
stomach, which were probably related to
the route of exposure. The confidence in
DEREK's prediction of noncarcinogenic-
ity is low, and the liver is identified as a
possible site oftumor formation.
24. Oxymetholone. Oxymetholone was
predicted to be a mutagen by DEREK as a
result of the presence of the ax,-unsatu-
rated ketone functionality, which may
exhibit electrophilic and hence DNA reac-
tivity. It gave a negative response in the
Ames test. Sites affected in the subchronic
study include the mammary glands in the
rat and the clitoris in the female mouse. The
promotional activity ofoxymetholone in rat
liver carcinogenesis has been reported (38).
It is an anabolic steroid with activities simi-
lar to those oftestosterone, a known rodent
carcinogen (39). Confidence in DEREK's
prediction ofnoncarcinogenicity is low.
25. Anthraquinone. Anthraquinone
gave a positive result in the Ames test with
and without S9 but was negative in a mouse
micronucleus assay. No subchronic study
data are available. 1-Hydroxyanthraquinone
has been reported to be a rat carcinogen
(40), but no evidence was available to indi-
cate that this was a significant metabolite of
anthraquinone. In the absence offurther evi-
dence, confidence in DEREK's prediction of
noncarcinogenicity is moderate.
26. Emodin. Emodin is predicted to be
a mutagen by DEREK, since it is a hydrox-
ylated anthraquinone that may exhibit
DNA intercalation. Experimental evidence
to support a noncovalent interaction ofan
oxidized metabolite ofemodin with DNA
has been reported (41). Emodin was muta-
genic in the Ames test only in the presence
of S9. It also gave a positive response in a
mouse micronucleus assay. Kidney lesions
were observed in both male and female rats
and mice in the subchronic assay. Although
some hydroxylated anthraquinones can act
as tumor promoters, emodin is reported to
be essentially inactive (42). The confidence
in DEREK's prediction ofnoncarcinogeni-
city is low.
27. Citral. Citral is predicted to be
a mutagen by DEREK because of the
presence of the cx,j unsaturated aldehyde
functionality, which may lead to electro-
philic and hence DNA reactivity. It gave
a negative response in the Ames test,
although it has been suggested that the tox-
icity to bacteria associated with lipophilic
compounds of this type may impede ade-
quate mutagenicity testing in Salmonella
(43). Citral also gave a negative response
in a mouse micronucleus assay. No sig-
nificant lesions were observed in the 14-
day subchronic study, although this was
not considered a strong predictor of the
histopathological effects that would be
observed in longer term studies. A longer
study may help in the interpretation ofthe
significance ofthe reported estrogenic (44)
and peroxisome proliferator (29) activities
ofcitral. In the absence offurther evidence,
confidence in DEREK's prediction ofnon-
carcinogenicity is moderate.
28. Sodium Nitrite. Sodium nitrite
gave a positive response in the Ames test. A
positive result in an in vivo mouse micro-
nucleus assay has been reported (45).
Forestomach squamous epithelial hyperpla-
sia observed in both rats and mice in the
subchronic study was described as minimal
to mild, and was probably related to the
route ofexposure. Rat forestomach squa-
mous papilloma have, however, previously
been reported in a sodium nitrite drinking-
water study (46). An increased incidence
offemale rat liver neoplasms has also been
observed in a feed, but not drinking-water,
study (47). The confidence in DEREK's
prediction of noncarcinogenicity is low,
and the forestomach is identified as a
possible site oftumor formation.
29.Cinnamaldehyde. DEREK predicts
cinnamaldehyde to be mutagenic, as a
result of the presence of the a,J unsatu-
rated aldehyde functionality, which may
lead to electrophilic and hence DNA
reactivity. It is reported to give a negative
result in the Ames test (8), although it has
been suggested that the toxicity to bacte-
ria associated with lipophilic compounds
of this type may impede adequate muta-
genicity testing in Salmonella (43).
Cinnamaldehyde also gave a negative
result in a mouse micronucleus assay.
Forestomach hyperplasia was observed in
2- or 3-week toxicity studies, and was
probably related to the route of exposure
(48). A study of this duration was not,
however, considered to be a strong predic-
tor of the histopathological effects that
would be observed in longer-term studies.
Confidence in DEREK's prediction of
noncarcinogenicity is moderate.
30. Vanadium Pentoxide. Vanadium
pentoxide gave a negative response in the
Ames test but a positive response in an in
vivo mouse micronucleus assay (49).
Vanadium compounds are known to inter-
fere with mitosis and chromosome distrib-
ution, although there are currently no data
to indicate that such compounds are car-
cinogenic in animals or man (49). Respira-
tory tract lesions were observed in both rats
and mice in the subchronic study, and
were probably related to the route ofexpo-
sure. Confidence in DEREK's prediction
ofnoncarcinogenicity is low.
Discussion
DEREKwas able to make predictions for all
ofthe chemicals in the exercise, including
five inorganic compounds. Seven chemicals
were predicted to be carcinogenic. Fol-
lowing expert evaluation ofsupplementary
data, two predicted carcinogens, scopo-
lamine hydrobromide and 1-chloro-2-
propanol, were thought unlikely to be
carcinogenic in either rats or mice, and the
predictions were therefore assigned a low
level ofconfidence. For 1,2-dihydro-2,2,4-
trimethylquinoline and diethanolamine,
there was a moderate level ofconfidence in
DEREK's prediction ofcarcinogenicity, but
carcinogenic activity was thought most
likely to arise from a different mechanism
to that proposed by DEREK.
A high level of confidence in both rats
and mice was associated with the predic-
tions for 3 of the 23 chemicals for which
DEREK provided no evidence ofcarcino-
genic activity. However, 11 of the 23
chemicals were thought likely to be car-
cinogenic, and predictions for these chemi-
cals were therefore assigned a low level of
confidence. If these compounds are found
to be carcinogens, they will identify the
need for new DEREK rules. Some of the
11 chemicals, such as isobutyraldehyde and
emodin, were predicted by DEREK to be
mutagenic. The toxicophore associated with
mutagenicity may at least in some cases also
form the basis ofany observed carcinogenic
activity. For other chemicals, potential toxi-
cophores were identified during the evalua-
tion of the supplementary data. Such
toxicophores include the alkenylbenzene
substructure present in methyleugenol, the
cobalt(II) ion present in cobalt sulfate and
the vanadium atom present in vanadium
pentoxide. Provided that adequate data can
be found in support ofthese toxicophores
following a detailed review ofthe literature,
new rules describing them will be added to
the DEREK carcinogenicity knowledge
Environmental Health Perspectives - Vol 104, Supplement 5 * October 1996 1071CA. MARCHANT AND THE DEREK COLLABORATIVE GROUP
base. For some chemicals, such as pri-
maclone and ethylene glycol monobutyl
ether, more work will be required before a
clearly defined toxicophore can be estab-
lished, if indeed these chemicals prove to
be carcinogenic.
The prediction exercise has also
identified possible modifications to existing
DEREK rules. Currently, DEREK predicts
that any nitroalkane or epoxide will be
mutagenic and carcinogenic. Salmonella
mutagenicity data for scopolamine hydro-
bromide and its structural analogues, how-
ever, suggest that the rule describing the
mutagenicity and carcinogenicity of epox-
ides should perhaps be modified to exclude
structures in which the epoxide is fused to
a bridged ring system. Supplementary data
considered for nitromethane have also
indicated that it may be appropriate to
restrict the rule describing the mutagenic-
ity and carcinogenicity of nitroalkanes to
secondary, and not primary or tertiary,
substrates. Additional evidence including
toxicological, mechanistic, and chemical
reactivity data will be sought before appro-
priate changes to the DEREK knowledge
base are implemented.
The development ofthe carcinogenicity
knowledge base is a current priority of the
DEREK project, and follows on from the
successful expansion of the knowledge
bases for other toxicological end points,
such as mutagenicity and skin sensitization.
Work is in progress to identify data that
can be used to further support and refine
existing DEREK rules, in particular the
FDA rules and rules that predict muta-
genic, but not carcinogenic, activity. In the
latter case, evidence of genotoxic carcino-
genic activity associated with the toxi-
cophore of a given mutagenicity rule will
allow the rule to be extended to include car-
cinogenicity as a toxicological end point.
Mechanistic aspects of the carcinogenic
process are also being reviewed with the
aim of identifying new toxicophores for
nongenotoxic carcinogenicity.
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